Oregon State University Researchers Develop Promising Lung Cancer Treatment Using Lipid Nanoparticles
Researchers at Oregon State University have developed a novel approach to address two major challenges associated with lung cancer: tumor growth and severe muscle loss. Their study, published in the Journal of Controlled Release, explores the use of lipid nanoparticles to deliver genetic material directly to cancer cells in the lungs. These nanoparticles are engineered to carry follistatin messenger RNA, which instructs cells to produce follistatin, a protein that slows tumor progression and supports muscle growth. The lipid nanoparticles are administered through the bloodstream and are directed to lung cancer tumors by binding with vitronectin, a protein found in blood serum. This method has shown a 2.5-fold greater reduction in tumor burden compared to conventional lipid nanoparticles, which tend to accumulate in the liver. 
